Because of its potential to cause adverse health effects in exposed people, a number of regulations and guidelines have been established for DEHP by various international, federal, and state agencies. These values are summarized in Table 12 .
carcinogenic potency, the incremental excess cancer risk per unit of exposure (usually g /l for water, mg /kg /day for food, and g/m 3 for air ).
Reference Dose (RfD ) ÐAn estimate ( with uncertainty spanning perhaps an order of magnitude ) of the daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects during a lifetime. The RfD is operationally derived from the NOAEL (from animal and human studies) by a consistent application of uncertainty factors (UFs ) that reflect various types of data used to estimate RfDs and an additional modifying factor, which is based on a professional judgment of the entire database on the chemical. The RfDs are not applicable to nonthreshold effects such as cancer.
Reportable Quantity ( RQ ) ÐThe quantity of a hazardous substance that is considered reportable under CER-CLA. Reportable quantities are ( 1) 1 pound or greater or ( 2) for selected substances, an amount established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities are measured over a 24 -hour period.
Reproductive Toxicity Ð The occurrence of adverse effects on the reproductive system that may result from exposure to a chemical. The toxicity may be directed to the reproductive organs and/ or the related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this system. Short -Term Exposure Limit ( STEL ) ÐThe maximum concentration to which workers can be exposed for up to 15 min continually. No more than four excursions are allowed per day, and there must be at least 60 min between exposure periods. The daily threshold limit value ± timeweighted average (TLV ± TWA ) may not be exceeded.
Target Organ Toxicity Ð This term covers a broad range of adverse effects on target organs or physiological systems (e.g., renal, cardiovascular ) extending from those arising through a single limited exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen ÐA chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value ( TLV ) ÐA concentration of a substance to which most workers can be exposed without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL.
Time-Weighted Average (TWA ) Ð An allowable exposure concentration averaged over a normal 8 -hour workday or 40 -hour workweek.
Toxic Dose (TD 50 ) Ð A calculated dose of a chemical, introduced by a route other than inhalation, which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Uncertainty Factor (UF ) ÐA factor used in operationally deriving the RfD from experimental data. UFs are intended to account for (1 ) the variation in sensitivity among the members of the human population, ( 2 ) the uncertainty in extrapolating animal data to the case of human, (3 ) the uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, and ( 4) the uncertainty in using LOAEL data rather than NOAEL data. Usually each of these factors is set equal to 10.
Appendix A: (User's guide)
Public health statement This section of the profile is a health effects summary written in nontechnical language. Its intended audience is the general public especially people living in the vicinity of a hazardous waste site or substance release. If the Public Health Statement was removed from the rest of the document, it would still communicate to the lay public essential information about the substance.
The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to sections in the profile that will provide more information on the given topic.
Tables and figures for Levels of Significant Exposure (LSE)
Tables ( 1, 2, and 3) and Figures (1 and 2 ) are used to summarize health effects by duration of exposure and endpoint and to illustrate graphically levels of exposure associated with those effects. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs for Less Serious and Serious health effects, or CELs. In addition, these tables and figures illustrate differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upperbound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. The LSE tables and figures can be used for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text.
The legends presented below demonstrate the application of these tables and figures. A representative example of LSE Table 1 and Figure 1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.
See LSE Table 1 (1) Route of exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. When sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 1± 3, respectively ) . LSE figures are limited to the inhalation (LSE Figure 1 ) and oral ( LSE Figure 2) routes.
(2) Exposure duration. Three exposure periods: acute ( 14 days or less ) ; intermediate ( 15 to 364 days ) ; and chronic (365 days or more ) are presented within each route of exposure. In this example, an inhalation study of intermediate duration exposure is reported.
(3) Health effect. The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects, but cancer. Systemic effects are further defined in the``System'' column of the LSE table.
(4) Key to figure. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to define a NOAEL and a Less Serious LOAEL ( also see the two``18r'' data points in Figure 1 ) .
(5) Species. The test species, whether animal or human, are identified in this column.
(6) Exposure frequency /duration. The duration of the study and the weekly and daily exposure regimen are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18 ), rats were exposed to [ substance x ] via inhalation for 13 weeks, 5 days per week, for 6 hours per day.
(7) System. This column further defines the systemic effects. These systems include: respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal / ocular.``Other'' refers to any systemic effect (e.g., a decrease in body weight ) not covered in these systems. In the example of key number 18, one systemic effect ( respiratory) was investigated in this study.
(8) NOAEL. A no -observed -adverse -effect level (NOAEL ) is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports an NOAEL of 3 ppm for the respiratory system which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnotè`b '') .
(9) LOAEL. A lowest -observed -adverse -effect level (LOAEL ) is the lowest exposure level used in the study that caused a harmful health effect. LOAELs have been classified into``Less Serious'' and``Serious'' effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The``Less Serious'' respiratory effect reported in key number 18 (hyperplasia ) occurred at an LOAEL of 10 ppm.
(10) Reference. The complete reference citation is given in the References section of the profile.
(11) CEL. A Cancer Effect Level ( CEL ) is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiological studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses which did not cause a measurable increase in cancer.
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote``b'' indicates the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm. See LSE Figure 1 LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure levels for particular exposure duration.
(13) Exposure duration. The same exposure periods appear as in the LSE (17) CEL. Key number 38r is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species (rat ) . The number 38 corresponds to the entry in the LSE table.
(18) Estimated upper-bound human cancer risk levels. This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels (q 1 *).
(19) Key to LSE figure. The Key explains the abbreviations and symbols used in the figure.
The section discusses health effects by end point. Human data are presented first, then animal data. Both are organized by route of exposure ( inhalation, oral, and dermal ) and by duration (acute, intermediate, and chronic) . In vitro data and data from parenteral routes ( intramuscular, intravenous, subcutaneous, etc. ) are also considered in this section. If data are located in the scientific literature, a table of genotoxicity information is included.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. MRLs for noncancer end points if derived, and the end points from which they were derived are indicated and discussed in the appropriate section (s ).
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in Identification of Data Needss.
Interpretation of MRLs
Where sufficient toxicologic information was available, MRLs were derived. MRLs are specific for route (inhalation or oral ) and duration (acute, intermediate, or chronic ) of exposure. Ideally, MRLs can be derived from all six exposure scenarios (e.g., Inhalation Ðacute, intermediate, chronic; OralÐ acute, intermediate, chronic) . These MRLs are not meant to support regulatory action, but to aquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans. They should help physicians and public health officials determine the safety of a community living near a substance emission, given the concentration of a contaminant in air or the estimated daily dose received via food or water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.
MRL users should be familiar with the toxicological information on which the number is based. Section 2.4,`R elevance to Public Health,'' contains basic information known about the substance. Other sections such as Section 2.6,``Interactions with Other Chemicals'' and Section 2.7,`P opulations that are Unusually Susceptible'' provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology used by EPA ( Barnes and Dourson, 1988; EPA, 1989a ) to derive reference doses (RfDs ) for lifetime exposure.
To derive an MRL, ATSDR generally selects the end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative ) is available for all potential effects (e.g., systemic, neurological, and developmental). In order to compare NOAELs and LOAELs for specific end points, all inhalation exposure levels are adjusted for 24 -hr exposures and all intermittent exposures for inhalation and oral routes of intermediate and chronic duration are adjusted for continuous exposure ( i.e., 7 d /wk ) . If the information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species ( when information from multiple species is available ) with the highest NOAEL that does not exceed any adverse effect levels. The NOAEL is the most suitable end point for deriving an MRL. When an NOAEL is not available, a Less Serious LOAEL can be used to derive an MRL, and a UF of 10 is employed. MRLs are not derived from Serious LOAELs. Additional UFs of 10 each are used for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance ) and for interspecies variability (extrapolation from animals to humans ). In deriving an MRL, these individual UFs are multiplied together. The product is then divided into the adjusted inhalation concentration or oral dosage selected from the study. UFs used in developing a substance -specific MRL are provided in the footnotes of the LSE Tables.  sec   second   SCE  sister chromatid (8) 
